Lipodystrophy in a cohort of human immunodeficiency virus-infected asian patients: Prevalence, associated factors, and psychological impact

Clinical Infectious Diseases

Volumn 35, Issue 10, 2002, Pages 1244-1249

  Paton, Nicholas I ^a   Earnest, Arul ^a   Ng, Yau Ming ^a   Karim, Fatimah ^a   Aboulhab, Jamila ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; GLUCOSE; INDINAVIR; LACTIC ACID; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ASIAN; BLOOD SAMPLING; BODY BUILD; CHINESE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JOB PERFORMANCE; LACTATE BLOOD LEVEL; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MOOD; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RISK FACTOR; SINGAPORE; SOCIAL BEHAVIOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ASIA; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; PREVALENCE;

EID: 0037111631     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344055     Document Type: Article

References (23)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
2. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999; 353:2093-9.
3. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000; 31:1482-7.
4. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231-9.
5. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15:1389-98.
6. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet 2001; 357:592-8.
7. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-16.
8. Chang KH, Kim JM, Song YG, Hong SK, Lee HC, Lim SK. Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals on HAART? J Infect 2002; 44:33-8.
9. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
10. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20:1183-97.
11. Ho TT, Chan KC, Wong KH, Lee SS. Indinavir-associated facial lipodystrophy in HIV-infected patients. AIDS Patient Care STDS 1999; 13:11-6.
12. Fraser HE, Ishihara M, Miller JE, et al. Prevalence survey of lipodystrophy in HIV-positive patients in Japan [abstract 017]. In: Program and Abstracts of the 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy (Toronto). Singapore: International Medical Press, 2000:12.
13. Rosenbaum K, Wang J, Pierson RN Jr, Kotler DP. Time-dependent variation in weight and body composition in healthy adults. JPEN J Parenter Enteral Nutr 2000; 24:52-5.
14. Shimokata H, Tobin JD, Muller DC, Elahi D, Coon PJ, Andres R. Studies in the distribution of body fat. I. Effects of age, sex, and obesity. J Gerontol 1989; 44:M66-73.
15. Paton NI, Macallan DC, Jebb SA, et al. Longitudinal changes in body composition measured with a variety of methods in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:119-27.
16. Mulligan K, Tai VW, Algren H, et al. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2001; 26:443-8.
17. Paton N, Ng Y-M, Chua Y-K, Aboulhab J, Karim F. Comparison of regional body composition changes in lipodystrophy with those of tuberculosis-related wasting [abstract 687]. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:304.
18. Engelson ES, Kotler DP, Tan Y, et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 1999; 69:1162-9.
19. The HIV Lipodystrophy Case Definition Study Group. An objective case definition of HIV lipodystrophy [abstract 31]. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:63.
20. Martinez E, Garcia-Viejo MA, Blanch L, Gatell JM. Lipodystrophy syndrome in patients with HIV infection: Quality of life issues. Drug Saf 2001; 24:157-66.
21. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-67.
22. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-9.
23. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15:717-23.